COMBINED TREATMENT OF NON-SMALL-CELL LUNG CANCER WITH BRAIN METASTASES: POTENTIALS FOR TARGETED THERAPY


Cite item

Full Text

Abstract

Based on own clinical experience, the authors have demonstrated the results of treatment of patients with non-small-cell lung cancer with brain metastases. The article also analyzes the data of numerous studies, which have developed the management of such patients. The most effective approach to the problem is a combination of radiation and chemotherapy. The potentials for targeted therapy using angiogenesis inhibitors (bevacizumab) and tyrosine kinase inhibitors (erlotinib and gefitinib) are discussed.

References

  1. Year 2000 Standard Statistical Report (1999) Central Brain Tumors Registry of the United States, pp. 7-18.
  2. Jill S. Barnholtz-Sloan, Andrew E, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22(14):2865-72.
  3. Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78(8):1781-8.
  4. Rades D, Raabe A, Bajrovic A, et al. Treatment of solitary brain metastasis. Resection followed by whole brain radiation therapy (WBRT) and a radiation boost to the metastatic site. Strahlenther Onkol 2004;180(3):144-7.
  5. DeAngelis LM, Mandell LR, Thaler HT, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24(6):798-805.
  6. Billing PS, Miller DL, Allen MS, et al. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001;122(3):548-53.
  7. Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer 2001;32(2):129-36.
  8. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665-72.
  9. Chidel MA, Suh JH, Reddy CA, et al. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 2000;47(4):993-9.
  10. Shehata MK, Young B, Reid B, et al. Stereotatic radiosurgery of 468 brain metastases < or = 2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys 2004 May;59(1):87-93.
  11. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 2004;45(2):253-7.
  12. Ebert BL, Niemierko E, Shaffer K, et al. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003;8(1):69-75.
  13. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599-605.
  14. Kaba SE, Kyritsis AP, Hess K, et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 1997;15:1063-70.
  15. Cotto C, Berille J, Souquet PJ, et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996;32A:69-71.
  16. Minotti V, Crino L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998;20:93-8.
  17. Pujol JL, Monnier A, Berille J, et al. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br J Cancer 1994;69:1136-40.
  18. Vinolas N, Graus F, Mellado B, et al. Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors. J Neurooncol 1997;35:145-8.
  19. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-65.
  20. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-54.
  21. Quantin X, Khial F, Reme-Saumon M, et al. Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 1999;26(1):35-9.
  22. Ye M, Yang H, Wang L. Palliative irradiation combined with chemotherapy for lung cancer with brain metastasis. Zhonghua Zhong Liu Za Zhi. 2001;23(6):505-06.
  23. Harita S, Mizuta A, Kuyama S, et al. Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only. Int J Clin Oncol 2005;10(1):63-8.
  24. Chang DB, Yang PC, Luh KT, et al. Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. Chest 1992;101(5):1293-97.
  25. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60(17):4959-67.
  26. Gordon MS, Margolin K, Talpaz M, et.al. Phase I and Clinical PharmacologyPhase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer. JCO 2001:843-50.
  27. Socinski M, Langer C, Huang J, et al. Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases. JCO 2009;1:5255-61.
  28. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010;16(1):269-78.
  29. Shigematsu H, Lin L, Takahashi T, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. JNCI 2005;97(5):339-46.
  30. Nguyen K.-S. H., Kobayashi S. et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 2009;10(4): 281-89
  31. Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-54.
  32. Das AK, Sato M, Story MD, et al. Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006;66:9601-08.
  33. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
  34. Gow CH, Chien CR, Chang YL, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008;14(1):162-68.
  35. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007;13:1511-15.
  36. Broniscer A, Baker S, Stewart C, et al. Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma. Clin Cancer Res 2009;15:701-7.
  37. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010;5(7):950-5.
  38. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011;37(3):624-31.
  39. Ceresoli G. L., Cappuzzo F, Gregorc V. et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-47.
  40. Chiu CH, Tsai CM, Chen YM et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005;47(1):129.
  41. Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007;57(3):359.
  42. Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99(2):283-86.
  43. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11(6):521-29.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies